Helus Pharma reported positive Phase 3 APPROACH results for HLP003 in adults with major depressive disorder: placebo-adjusted MADRS reductions of -7.6 points at Week 6 and -7.0 points at Week 12, each p<0.0001.
HELP · Helus Pharma Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $6.78
- Open
- $7.00
- Day range
- $6.51–7.14
- 52-week closing range
- $3.87–14.02
- Average volume, 30 days
- 2.0M
- Short interest
- 2.7M · 3.3% of shares · 2.1 days
- Short volume, last session
- 37%
- Last earnings
- Nov 16, 2026
- Price history
- Mar 2020 to Nov 2026
Up next
Latest documents
Helus Pharma completed enrollment in Phase 3 APPROACH for HLP003 in MDD, with topline data on track for Q4 2026. Cash totaled $171.1 million and net loss was $103.1 million for the quarter ended September 30, 2026.
Helus Pharma Inc. will present topline results from its Phase 3 APPROACH study evaluating HLP003 in major depressive disorder during a webcast at 8:00 a.m. EDT on November 16, 2026.
Helus Pharma Inc. reported a six-month net loss of $150,910 thousand for the period ended September 30, 2026, versus $58,335 thousand in 2025, while cash reached $171,071 thousand at September 30, 2026.
Healus Pharma expects an OO3 phase three major depressive disorder readout later this quarter, plans a 2028 NDA filing and approval, and reported approximately $165 million on its balance sheet.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HELP
this stock
Helus Pharma Inc.
|
$541.16M | -17.1% | — | — | 3.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 56
Helus Pharma reported positive Phase 3 APPROACH results for HLP003 in adults with major depressive disorder: placebo-adjusted MADRS reductions of -7.6 points at Week 6 and -7.0 points at Week 12, each p<0.0001.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HELP | -23.5% | -35.4% | +44.6% | -36.0% | -17.1% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -18.0% | -29.1% | +50.2% | -30.7% | -22.1% |